210 related articles for article (PubMed ID: 11057353)
1. Allergic conjunctivitis and contact lenses: experience with olopatadine hydrochloride 0.1% therapy.
Brodsky M
Acta Ophthalmol Scand Suppl; 2000; (230):56-9. PubMed ID: 11057353
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model.
Abelson MB; Welch DL
Acta Ophthalmol Scand Suppl; 2000; (230):60-3. PubMed ID: 11057354
[TBL] [Abstract][Full Text] [Related]
3. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model.
Abelson MB; Lanier RQ
Acta Ophthalmol Scand Suppl; 1999; (228):53-6. PubMed ID: 10337434
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate.
Aguilar AJ
Acta Ophthalmol Scand Suppl; 2000; (230):52-5. PubMed ID: 11057352
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model.
Brodsky M; Berger WE; Butrus S; Epstein AB; Irkec M
Eye Contact Lens; 2003 Apr; 29(2):113-6. PubMed ID: 12695716
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model.
Deschenes J; Discepola M; Abelson M
Acta Ophthalmol Scand Suppl; 1999; (228):47-52. PubMed ID: 10337433
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis.
Yaylali V; Demirlenk I; Tatlipinar S; Ozbay D; Esme A; Yildirim C; Ozden S
Acta Ophthalmol Scand; 2003 Aug; 81(4):378-82. PubMed ID: 12859265
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis.
Abelson MB; Turner D
Clin Ther; 2003 Mar; 25(3):931-47. PubMed ID: 12852709
[TBL] [Abstract][Full Text] [Related]
9. Comparison of olopatadine and fluorometholone in contact lens-induced papillary conjunctivitis.
Khurana S; Sharma N; Agarwal T; Chawla B; Velpandian T; Tandon R; Titiyal JS
Eye Contact Lens; 2010 Jul; 36(4):210-4. PubMed ID: 20531202
[TBL] [Abstract][Full Text] [Related]
10. A review of olopatadine for the treatment of ocular allergy.
Abelson MB
Expert Opin Pharmacother; 2004 Sep; 5(9):1979-94. PubMed ID: 15330735
[TBL] [Abstract][Full Text] [Related]
11. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration.
Vogelson CT; Abelson MB; Pasquine T; Stephens DM; Gamache DA; Gross RD; Robertson SM; Yanni JM
Allergy Asthma Proc; 2004; 25(1):69-75. PubMed ID: 15055565
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model.
Lanier BQ; Finegold I; D'Arienzo P; Granet D; Epstein AB; Ledgerwood GL
Curr Med Res Opin; 2004 Aug; 20(8):1227-33. PubMed ID: 15324525
[TBL] [Abstract][Full Text] [Related]
13. A review of the use of olopatadine in allergic conjunctivitis.
McGill JI
Int Ophthalmol; 2004 May; 25(3):171-9. PubMed ID: 15847317
[TBL] [Abstract][Full Text] [Related]
14. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.
Leonardi A; Abelson MB
Clin Ther; 2003 Oct; 25(10):2539-52. PubMed ID: 14667955
[TBL] [Abstract][Full Text] [Related]
15. A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%.
Artal MN; Luna JD; Discepola M
Acta Ophthalmol Scand Suppl; 2000; (230):64-5. PubMed ID: 11057355
[TBL] [Abstract][Full Text] [Related]
16. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms.
Lanier BQ; Gross RD; Marks BB; Cockrum PC; Juniper EF
Ann Allergy Asthma Immunol; 2001 Jun; 86(6):641-8. PubMed ID: 11428736
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
Abelson MB; Greiner JV
Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge.
Lanier BQ; Abelson MB; Berger WE; Granet DB; D'Arienzo PA; Spangler DL; Kägi MK
Clin Ther; 2002 Jul; 24(7):1161-74. PubMed ID: 12182260
[TBL] [Abstract][Full Text] [Related]
19. Efficiency of olopatadine hydrochloride 0.1% in the treatment of vernal keratoconjunctivitis and goblet cell density.
Corum I; Yeniad B; Bilgin LK; Ilhan R
J Ocul Pharmacol Ther; 2005 Oct; 21(5):400-5. PubMed ID: 16245967
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.
Spangler DL; Bensch G; Berdy GJ
Clin Ther; 2001 Aug; 23(8):1272-80. PubMed ID: 11558863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]